Literature DB >> 4008618

In vitro and in vivo cholera toxin production by classical and El Tor isolates of Vibrio cholerae.

P C Turnbull, J V Lee, M D Miliotis, C S Still, M Isaäcson, Q S Ahmad.   

Abstract

A comparative study was carried out on the in vitro production of cholera toxin by 19 Vibrio cholerae El Tor isolates from patients with cholera in South Africa, one El Tor isolate from a patient in Malawi (a country approximately 1000 km north-northeast of South Africa), 6 El Tor and 12 classical type isolates from patients in Bangladesh, and 5 culture collection classical strains. Identical phage types and indistinguishable toxigenicities among the South African and Malawi V. cholerae, representing isolations obtained over a 10-year period, indicated that essentially a single strain was involved in the cholera of these regions. Similarly, phage typing and toxin profiles indicated that the 12 classical and 6 El Tor V. cholerae cultures in Bangladesh, all isolated in November 1983, represented just two strains. As assessed by titrations in Y-1 mouse adrenal and Chinese hamster ovary cell lines, the general order of toxigenicities was Bangladesh and culture collection classical greater than Bangladesh El Tor greater than southern African El Tor. The African isolates consistently gave rise to very low titers. Their relative reluctance to produce the toxin in vitro compared with the culture collection classical strains, particularly strain 569B, was confirmed by rocket electrophoresis. In somewhat of a contrast, maximum in vivo titers in rice water stools from cholera patients in South Africa and from both classical and El Tor type cholera patients in Bangladesh were essentially equal. It is postulated that under the continuous culture conditions that occur in vivo, cholera toxin concentrations can accumulate to a maximum level, depending on the rate of purging by the diarrheal fluid rather than the toxigenicity of the infecting stain. The relevance of these findings to the relative severities of classical and El Tor types of cholera is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008618      PMCID: PMC271811          DOI: 10.1128/jcm.21.6.884-890.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Experimental cholera in infant rabbits: a method for chemotherapeutic investigation.

Authors:  N K DUTTA; M K HABBU
Journal:  Br J Pharmacol Chemother       Date:  1955-06

2.  The recent cholera outbreak in the South African gold mining industry. A preliminary report.

Authors:  M Isaäcson; K R Clarke; G H Ellacombe; W A Smit; P Smit; H J Koornhof; L S Smith; L J Kriel
Journal:  S Afr Med J       Date:  1974-12-14

3.  Pathogenesis of experimental cholera: biologic ativities of purified procholeragen A.

Authors:  R A Finkelstein; P Atthasampunna; M Chulasamaya; P Charunmethee
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

4.  A study of the pathogenesis of El Tor and classical cholera vibrios in infant rabbits.

Authors:  N B Oza; N K Dutta
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

5.  Factors influencing in vitro skin permeability factor production by Vibrio cholerae.

Authors:  S H Richardson
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

6.  Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development.

Authors:  J J Mekalanos; D J Swartz; G D Pearson; N Harford; F Groyne; M de Wilde
Journal:  Nature       Date:  1983 Dec 8-14       Impact factor: 49.962

7.  Simultaneous classical and El Tor cholera in Bangladesh.

Authors:  M U Khan; A R Samadi; M I Huq; M Yunus; A Eusof
Journal:  J Diarrhoeal Dis Res       Date:  1984-03

8.  A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.

Authors:  J P Craig
Journal:  Nature       Date:  1965-08-07       Impact factor: 49.962

9.  Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man.

Authors:  D J Evans; D G Evans; S L Gorbach
Journal:  Infect Immun       Date:  1973-11       Impact factor: 3.441

10.  Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli.

Authors:  D J Evans; D G Evans; S L Gorbach
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

View more
  6 in total

1.  Role of platelet-activating factor in Chinese hamster ovary cell responses to cholera toxin.

Authors:  N M Thielman; M Marcinkiewicz; J Sarosiek; G D Fang; R L Guerrant
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

Review 2.  Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp.

Authors:  J M Janda; C Powers; R G Bryant; S L Abbott
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

Review 3.  Waterborne transmission and the evolution of virulence among gastrointestinal bacteria.

Authors:  P W Ewald
Journal:  Epidemiol Infect       Date:  1991-02       Impact factor: 2.451

4.  Selective and Efficient Elimination of Vibrio cholerae with a Chemical Modulator that Targets Glucose Metabolism.

Authors:  Young Taek Oh; Hwa Young Kim; Eun Jin Kim; Junhyeok Go; Wontae Hwang; Hyoung Rae Kim; Dong Wook Kim; Sang Sun Yoon
Journal:  Front Cell Infect Microbiol       Date:  2016-11-16       Impact factor: 5.293

5.  Towards new cholera prophylactics and treatment: Crystal structures of bacterial enterotoxins in complex with GM1 mimics.

Authors:  Julie Elisabeth Heggelund; Alasdair Mackenzie; Tobias Martinsen; Joel Benjamin Heim; Pavel Cheshev; Anna Bernardi; Ute Krengel
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

6.  Strong Inhibition of Cholera Toxin B Subunit by Affordable, Polymer-Based Multivalent Inhibitors.

Authors:  Diksha Haksar; Eyleen de Poel; Linda Quarles van Ufford; Sumati Bhatia; Rainer Haag; Jeffrey Beekman; Roland J Pieters
Journal:  Bioconjug Chem       Date:  2019-01-24       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.